

Marta Korbonits

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4359821/publications.pdf>

Version: 2024-02-01

322
papers

19,098
citations

11608

70
h-index

16127

124
g-index

332
all docs

332
docs citations

332
times ranked

17396
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST ₅) in pituitary and pancreatic neuroendocrine tumors. <i>Molecular Oncology</i> , 2022, 16, 764-779.	2.1	6
2	Treatment of congenital adrenal hyperplasia in children aged 0–3 years: a retrospective multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure. <i>European Journal of Endocrinology</i> , 2022, 186, 587-596.	1.9	7
3	Molecular genetic testing in the management of pituitary disease. <i>Clinical Endocrinology</i> , 2022, 97, 424-435.	1.2	18
4	Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1906-1919.	1.8	12
5	Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes. <i>Journal of the Endocrine Society</i> , 2022, 6, bvab190.	0.1	5
6	Glucose and lipid metabolism abnormalities in Cushing's syndrome. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	24
7	Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3313-e3320.	1.8	7
8	Biochemical discrepancies in the evaluation of the somatotroph axis: Elevated GH or IGF-1 levels do not always diagnose acromegaly. <i>Growth Hormone and IGF Research</i> , 2022, 64, 101467.	0.5	6
9	Ockham's Razor for a Retinal Lesion and Acromegaly and Breaking the Vicious Circle. <i>Journal of the Endocrine Society</i> , 2022, 6, .	0.1	2
10	AIP variant causing familial prolactinoma. <i>Pituitary</i> , 2021, 24, 48-52.	1.6	9
11	Real-World Estimates of Adrenal Insufficiency-Related Adverse Events in Children With Congenital Adrenal Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e192-e203.	1.8	20
12	Clinical Outcomes and Complications of Pituitary Blastoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 351-363.	1.8	23
13	Pre-operative serum inflammation-based scores in patients with pituitary adenomas. <i>Pituitary</i> , 2021, 24, 334-350.	1.6	21
14	Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1183-e1194.	1.8	48
15	Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. <i>Endocrine Connections</i> , 2021, 10, 76-83.	0.8	12
16	Patients with rare endocrine conditions have corresponding views on unmet needs in clinical research. <i>Endocrine</i> , 2021, 71, 561-568.	1.1	4
17	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa205.	0.1	31
18	The clinical aspects of pituitary tumour genetics. <i>Endocrine</i> , 2021, 71, 663-674.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Genetics of Acromegaly and Gigantism. <i>Journal of Clinical Medicine</i> , 2021, 10, 1377.	1.0	21
20	Molecular characterization of DICER1-mutated pituitary blastoma. <i>Acta Neuropathologica</i> , 2021, 141, 929-944.	3.9	11
21	International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry. <i>European Journal of Endocrinology</i> , 2021, 184, 553-563.	1.9	21
22	Serum Inflammation-based Scores in Endocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3796-e3819.	1.8	19
23	Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence. <i>Endocrine Connections</i> , 2021, 10, 387-400.	0.8	4
24	GHRH secretion from a pancreatic neuroendocrine tumor causing gigantism in a patient with MEN1. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2021, 2021, .	0.2	6
25	Cabergoline reduces 3-methoxytyramine in a SDHC patient with metastatic paraganglioma and prolactinoma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2021, 2021, .	0.2	1
26	RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas. <i>Oncogene</i> , 2021, 40, 6354-6368.	2.6	11
27	Management of children and young people with idiopathic pituitary stalk thickening, central diabetes insipidus, or both: a national clinical practice consensus guideline. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 662-676.	2.7	21
28	Natriuretic Peptide Expression and Function in GH3 Somatolactotropes and Feline Somatotrope Pituitary Tumours. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1076.	1.8	1
29	The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2021, 33, e13052.	1.2	6
30	Sex-biased islet β cell dysfunction is caused by the MODY MAFA S64F variant by inducing premature aging and senescence in males. <i>Cell Reports</i> , 2021, 37, 109813.	2.9	27
31	Approach to the Patient with Pseudoacromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, , .	1.8	2
32	Case Report: Malignant Primary Sellar Paraganglioma With Unusual Genetic and Imaging Features. <i>Frontiers in Oncology</i> , 2021, 11, 739255.	1.3	3
33	Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 314-326.	1.8	30
34	Acquired Ectopic Posterior Pituitary Bright Spot Due to Vasculotoxic Snakebite. <i>AACE Clinical Case Reports</i> , 2020, 6, e207-e211.	0.4	2
35	Update on the Genetics of Pituitary Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 433-452.	1.2	22
36	Unusual Combination of MEN-1 and the Contiguous Gene Deletion Syndrome of CAH and Ehlers-Danlos Syndrome (CAH-X). <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa077.	0.1	1

#	ARTICLE	IF	CITATIONS
37	The role of the tumour microenvironment in the angiogenesis of pituitary tumours. <i>Endocrine</i> , 2020, 70, 593-606.	1.1	22
38	The tumour microenvironment of pituitary neuroendocrine tumours. <i>Frontiers in Neuroendocrinology</i> , 2020, 58, 100852.	2.5	29
39	Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms. <i>Endocrine Reviews</i> , 2020, 41, 821-846.	8.9	61
40	XAF1 as a modifier of p53 function and cancer susceptibility. <i>Science Advances</i> , 2020, 6, eaba3231.	4.7	37
41	Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 278-291.	5.5	60
42	Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. <i>Endocrine</i> , 2020, 67, 651-658.	1.1	19
43	Pachydermoperiostosis mimicking the acral abnormalities of acromegaly. <i>Endocrine</i> , 2020, 67, 499-500.	1.1	8
44	Phenotypic and genotypic features of a large kindred with a germline AIP variant. <i>Clinical Endocrinology</i> , 2020, 93, 146-153.	1.2	3
45	Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2247-e2260.	1.8	37
46	Identification of a TMEM127 variant in a patient with paraganglioma and acromegaly. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.2	4
47	Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation-Positive Child. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3539-3544.	1.8	41
48	Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. <i>Acta Neuropathologica Communications</i> , 2019, 7, 172.	2.4	65
49	Pediatric Parathyroid Carcinoma: A Case Report and Review of the Literature. <i>Journal of the Endocrine Society</i> , 2019, 3, 2224-2235.	0.1	15
50	Redefining the perioperative stress response: a narrative review. <i>British Journal of Anaesthesia</i> , 2019, 123, 570-583.	1.5	77
51	Clinical and Pathological Aspects of Silent Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2473-2489.	1.8	120
52	Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation. <i>Cell Reports</i> , 2019, 27, 1461-1471.e4.	2.9	17
53	Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. <i>Oncogene</i> , 2019, 38, 5381-5395.	2.6	59
54	Phosphodiesterases and cAMP Pathway in Pituitary Diseases. <i>Frontiers in Endocrinology</i> , 2019, 10, 141.	1.5	5

#	ARTICLE	IF	CITATIONS
55	Pseudoacromegaly. <i>Frontiers in Neuroendocrinology</i> , 2019, 52, 113-143.	2.5	23
56	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 213-220.	5.5	86
57	Pituitary Pathology and Gene Expression in Acromegalic Cats. <i>Journal of the Endocrine Society</i> , 2019, 3, 181-200.	0.1	17
58	Genetics of Pituitary Tumours. <i>Experientia Supplementum</i> (2012), 2019, 111, 171-211.	0.5	6
59	MON-460 Pasireotide Treatment Inhibits Cytokine Release from Pituitary Adenoma-Associated Fibroblasts: Is This Mechanism Playing a Key Role in Its Effect?. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	3
60	Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion. <i>Endocrine Connections</i> , 2019, 8, 326-337.	0.8	3
61	The current landscape of European registries for rare endocrine conditions. <i>European Journal of Endocrinology</i> , 2019, 180, 89-98.	1.9	25
62	Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. <i>Endocrine-Related Cancer</i> , 2019, 26, 853-865.	1.6	35
63	Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects. <i>Journal of Endocrinology</i> , 2019, 240, R21-R45.	1.2	55
64	Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongata tumour, adrenal adenoma, and follicular thyroid nodules. <i>Endokrynologia Polska</i> , 2019, 70, 213-217.	0.3	7
65	Assessment of Cardiovascular Changes following Trans-sphenoidal Surgery in Acromegalic Patients. <i>Neurology India</i> , 2019, 67, 1170.	0.2	0
66	MON-462 Cytokine Network in Pituitary Adenomas and Its Role in the Tumor Microenvironment: Focus on Macrophages. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
67	SAT-462 AIP Mutation-Positive Patients with Somatotropinomas End up Taller and Requiring Radiotherapy More Often Compared to AIP Mutation-Negative Patients: Data from 784 Familial and Young-Onset Cases. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
68	OR16-1 Best of The Journal of Clinical Endocrinology & Metabolism: Macimorelin as a Diagnostic Test for Adult GH Deficiency. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
69	Risk category system to identify pituitary adenoma patients with <i>AIP</i> mutations. <i>Journal of Medical Genetics</i> , 2018, 55, 254-260.	1.5	35
70	UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS. <i>Endocrine Practice</i> , 2018, 24, 473-488.	1.1	55
71	Metabolic Syndrome in Cushing's Syndrome Patients. <i>Frontiers of Hormone Research</i> , 2018, 49, 85-103.	1.0	42
72	<i>In vivo</i> bioassay to test the pathogenicity of missense human <i>AIP</i> variants. <i>Journal of Medical Genetics</i> , 2018, 55, 522-529.	1.5	15

#	ARTICLE	IF	CITATIONS
73	A novel <i>DICER1</i> mutation in familial multinodular goitre. <i>Clinical Endocrinology</i> , 2018, 89, 110-112.	1.2	5
74	CantÃ syndrome with coexisting familial pituitary adenoma. <i>Endocrine</i> , 2018, 59, 677-684.	1.1	13
75	<i>MAFA</i> missense mutation causes familial insulinomatosis and diabetes mellitus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 1027-1032.	3.3	88
76	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. <i>European Journal of Endocrinology</i> , 2018, 178, 265-276.	1.9	196
77	Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas. <i>Molecular and Cellular Endocrinology</i> , 2018, 476, 103-109.	1.6	10
78	Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. <i>Acta Neuropathologica</i> , 2018, 135, 757-777.	3.9	106
79	International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. <i>Pharmacological Reviews</i> , 2018, 70, 763-835.	7.1	163
80	Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland. <i>Oncotarget</i> , 2018, 9, 9177-9198.	0.8	31
81	Proteomic Analysis of the Human Anterior Pituitary Gland. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 759-769.	1.0	23
82	Coexisting pituitary and non-pituitary gigantism in the same family. <i>Clinical Endocrinology</i> , 2018, 89, 887-888.	1.2	4
83	Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome. <i>Case Reports in Endocrinology</i> , 2018, 2018, 1-6.	0.2	6
84	Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-15.	0.6	9
85	CRAN-40. A NATIONAL UK GUIDELINE FOR MANAGING PITUITARY ADENOMAS IN CHILDREN AND YOUNG PEOPLE UNDER 19 YEARS DEVELOPED ACCORDING TO THE AGREE II FRAMEWORK. <i>Neuro-Oncology</i> , 2018, 20, i44-i45.	0.6	1
86	Macimorelin as a Diagnostic Test for Adult GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3083-3093.	1.8	71
87	Unusual AIP mutation and phenocopy in the family of a young patient with acromegalic gigantism. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	3
88	Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor. <i>European Journal of Endocrinology</i> , 2018, 178, 57-63.	1.9	37
89	Survivin as a potential therapeutic target of acetylsalicylic acid in pituitary adenomas. <i>Oncotarget</i> , 2018, 9, 29180-29192.	0.8	7
90	A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	4

#	ARTICLE	IF	CITATIONS
91	Metformin prevents metabolic side effects during systemic glucocorticoid treatment. <i>European Journal of Endocrinology</i> , 2017, 176, 349-358.	1.9	35
92	From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. <i>Endocrine-Related Cancer</i> , 2017, 24, C5-C8.	1.6	262
93	The genetic background of acromegaly. <i>Pituitary</i> , 2017, 20, 10-21.	1.6	65
94	Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2017, 125, 365-367.	0.6	7
95	A unique haplotype of RCCX copy number variation: from the clinics of congenital adrenal hyperplasia to evolutionary genetics. <i>European Journal of Human Genetics</i> , 2017, 25, 702-710.	1.4	10
96	Pachydermoperiostosis Masquerading as Acromegaly. <i>Journal of the Endocrine Society</i> , 2017, 1, 109-112.	0.1	10
97	PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex. <i>European Journal of Endocrinology</i> , 2017, 177, K7-K12.	1.9	36
98	Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 143-153.	1.2	28
99	Genetic Aspects of Pituitary Adenomas. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 335-374.	1.2	47
100	Pituitary Carcinoma in a Patient with an SDHB Mutation. <i>Endocrine Pathology</i> , 2017, 28, 320-325.	5.2	50
101	Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas. <i>Pathology and Oncology Research</i> , 2017, 23, 633-641.	0.9	19
102	Social, educational and vocational outcomes in patients with childhood-onset and young-adult-onset growth hormone deficiency. <i>Clinical Endocrinology</i> , 2017, 86, 526-533.	1.2	6
103	AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation. <i>Endocrine Connections</i> , 2017, 6, 914-925.	0.8	18
104	AIP and the somatostatin system in pituitary tumours. <i>Journal of Endocrinology</i> , 2017, 235, R101-R116.	1.2	27
105	Pseudoacromegaly: A Differential Diagnostic Problem for Acromegaly With a Genetic Solution. <i>Journal of the Endocrine Society</i> , 2017, 1, 1104-1109.	0.1	14
106	In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. <i>European Journal of Endocrinology</i> , 2017, 177, 257-266.	1.9	12
107	Succinate Dehydrogenase B (SDHB)-Associated Bladder Paragangliomas. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e131-e136.	0.9	9
108	Increased Population Risk of AIP-Related Acromegaly and Gigantism in Ireland. <i>Human Mutation</i> , 2017, 38, 78-85.	1.1	25

#	ARTICLE	IF	CITATIONS
109	Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. <i>Clinical Endocrinology</i> , 2017, 86, 286-296.	1.2	34
110	Fatal Carney Complex in Siblings Due to De Novo Large Gene Deletion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3924-3927.	1.8	17
111	Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2017, 2017, .	0.2	8
112	Genetics of pituitary adenomas. <i>Neurology India</i> , 2017, 65, 577.	0.2	17
113	Genetic Causes of Familial Pituitary Tumors. , 2017, , 185-211.		2
114	Echocardiographic improvements following transsphenoidal surgery for acromegaly. <i>Neurology India</i> , 2017, 65, 1225.	0.2	0
115	Novel Germline p.Gly42Val Mutation in a Family with Multiple Endocrine Neoplasia Type 1 - Excellent Response of Prolactinoma to Cabergoline. <i>Annals of Clinical and Laboratory Science</i> , 2017, 47, 606-610.	0.2	1
116	Diagnosis of Acromegaly. , 2016, , 223-229.		0
117	Clinical Features of Acromegaly. , 2016, , 212-222.		0
118	Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. <i>World Journal of Diabetes</i> , 2016, 7, 572.	1.3	51
119	Clinicopathologic features of familial pituitary adenomas. <i>Diagnostic Histopathology</i> , 2016, 22, 85-91.	0.2	4
120	Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2364-2374.	1.2	139
121	AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience. <i>Endocrine</i> , 2016, 53, 402-411.	1.1	20
122	Gigantism: X-linked acrogigantism and GPR101 mutations. <i>Growth Hormone and IGF Research</i> , 2016, 30-31, 64-69.	0.5	20
123	Signaling network map of the aryl hydrocarbon receptor. <i>Journal of Cell Communication and Signaling</i> , 2016, 10, 341-346.	1.8	7
124	Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance. <i>Endocrine</i> , 2016, 54, 778-787.	1.1	15
125	Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. <i>Acta Neuropathologica Communications</i> , 2016, 4, 56.	2.4	110
126	Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With Missense AIP Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3144-3154.	1.8	47

#	ARTICLE	IF	CITATIONS
127	Novel Genetic Causes of Pituitary Adenomas. <i>Clinical Cancer Research</i> , 2016, 22, 5030-5042.	3.2	107
128	cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors. <i>Endocrine-Related Cancer</i> , 2016, 23, 419-431.	1.6	29
129	Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG) – Diagnosis and Management. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1927-1930.	1.8	48
130	Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. <i>European Journal of Endocrinology</i> , 2016, 174, 355-362.	1.9	56
131	Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. <i>European Journal of Endocrinology</i> , 2016, 174, 241-250.	1.9	122
132	Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma. <i>Pituitary</i> , 2016, 19, 50-56.	1.6	15
133	Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly?. <i>Neurology India</i> , 2016, 64, 252.	0.2	19
134	Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1. <i>International Journal of Pediatric Endocrinology (Springer)</i> , 2015, 2015, 15.	1.6	17
135	Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas. <i>PLoS ONE</i> , 2015, 10, e0117107.	1.1	59
136	Studying Cat (<i>Felis catus</i>) Diabetes: Beware of the Acromegalic Imposter. <i>PLoS ONE</i> , 2015, 10, e0127794.	1.1	51
137	Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. <i>PLoS ONE</i> , 2015, 10, e0143830.	1.1	16
138	Chrelin. <i>Molecular Metabolism</i> , 2015, 4, 437-460.	3.0	810
139	15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and pheochromocytomas or paragangliomas. <i>Endocrine-Related Cancer</i> , 2015, 22, T105-T122.	1.6	59
140	The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 481-487.	1.0	3
141	Prostatic hyperplasia in acromegaly, a myth or reality: a case-control study. <i>European Journal of Endocrinology</i> , 2015, 172, 97-106.	1.9	10
142	GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database. <i>European Journal of Endocrinology</i> , 2015, 172, 371-381.	1.9	55
143	Clinical profile and outcome of patients with acromegaly according to the 2014 consensus guidelines: Impact of a multi-disciplinary team. <i>Neurology India</i> , 2015, 63, 360.	0.2	16
144	Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E531-E541.	1.8	145

#	ARTICLE	IF	CITATIONS
145	Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1699-1708.	1.8	144
146	Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia. <i>Endocrine</i> , 2015, 50, 496-503.	1.1	5
147	Multi-parametric cardiovascular magnetic resonance imaging detects subclinical myocardial involvement in patients diagnosed with pheochromocytoma. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2015, 17, P271.	1.6	0
148	Evaluation of genotype-phenotype relationships in patients referred for endocrine assessment in suspected Pendred syndrome. <i>European Journal of Endocrinology</i> , 2015, 172, 217-226.	1.9	15
149	The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E997-E1004.	1.8	163
150	Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1242-E1254.	1.8	144
151	The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. <i>European Journal of Endocrinology</i> , 2015, 173, 655-664.	1.9	255
152	Metabolic comorbidities in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2015, 173, M133-M157.	1.9	128
153	An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2015, 2015, 140105.	0.2	9
154	Common Genetic Variants of the Human Steroid 21-Hydroxylase Gene (CYP21A2) Are Related to Differences in Circulating Hormone Levels. <i>PLoS ONE</i> , 2014, 9, e107244.	1.1	12
155	The role of ghrelin in weight-regulation disorders: Implications in clinical practice. <i>Hormones</i> , 2014, 13, 458-75.	0.9	21
156	Combination of 13-Cis Retinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice. <i>Endocrinology</i> , 2014, 155, 2377-2390.	1.4	15
157	Fasting and postprandial liver glycogen content in patients with type 1 diabetes mellitus after successful pancreas-kidney transplantation with systemic venous insulin delivery. <i>Clinical Endocrinology</i> , 2014, 80, 208-213.	1.2	8
158	Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. <i>European Journal of Endocrinology</i> , 2014, 171, 659-666.	1.9	46
159	Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas. <i>European Journal of Endocrinology</i> , 2014, 171, 705-710.	1.9	12
160	Epidemiology and etiopathogenesis of pituitary adenomas. <i>Journal of Neuro-Oncology</i> , 2014, 117, 379-394.	1.4	181
161	Clinical Experience in the Screening and Management of a Large Kindred With Familial Isolated Pituitary Adenoma Due to an Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1122-1131.	1.8	53
162	Metformin mode of action and clinical implications for diabetes and cancer. <i>Nature Reviews Endocrinology</i> , 2014, 10, 143-156.	4.3	955

#	ARTICLE	IF	CITATIONS
163	Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. <i>Acta Neuropathologica</i> , 2014, 128, 111-122.	3.9	211
164	Effects of smoking cessation on β -cell function, insulin sensitivity, body weight, and appetite. <i>European Journal of Endocrinology</i> , 2014, 170, 219-227.	1.9	67
165	Familial pituitary tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 124, 339-360.	1.0	21
166	Preface. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 124, ix.	1.0	0
167	Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2018-2029.	1.8	31
168	Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2014, 2014, 140074.	0.2	13
169	Genetics of Pituitary Adenomas. <i>Frontiers of Hormone Research</i> , 2013, 41, 111-140.	1.0	61
170	The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release. <i>FASEB Journal</i> , 2013, 27, 5112-5121.	0.2	25
171	Genetics of the Ghrelin System. <i>Endocrine Development</i> , 2013, 25, 25-40.	1.3	8
172	Novel pathway for somatostatin analogs in patients with acromegaly. <i>Trends in Endocrinology and Metabolism</i> , 2013, 24, 238-246.	3.1	126
173	ACTH-secreting Crooke cell carcinoma of the pituitary. <i>European Journal of Clinical Investigation</i> , 2013, 43, 20-26.	1.7	38
174	Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. <i>Molecular and Cellular Endocrinology</i> , 2013, 365, 303-308.	1.6	56
175	Characterization of SNARE Proteins in Human Pituitary Adenomas: Targeted Secretion Inhibitors as a New Strategy for the Treatment of Acromegaly?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1918-E1926.	1.8	8
176	MicroRNAs: Suggested role in pituitary adenoma pathogenesis. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 889-895.	1.8	29
177	A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype. <i>PLoS Genetics</i> , 2013, 9, e1003350.	1.5	125
178	A Comprehensive Next Generation Sequencing-Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1248-E1256.	1.8	92
179	CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus. <i>Journal of Endocrinology</i> , 2013, 219, 79-88.	1.2	26
180	Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker. <i>Stress</i> , 2012, 15, 554-561.	0.8	10

#	ARTICLE	IF	CITATIONS
181	Combined blockade of signalling pathways shows marked anti-tumour potential in pheochromocytoma cell lines. <i>Journal of Molecular Endocrinology</i> , 2012, 49, 79-96.	1.1	44
182	Expression of guanylyl cyclase-B (GC-B/NPR2) receptors in normal human fetal pituitaries and human pituitary adenomas implicates a role for C-type natriuretic peptide. <i>Endocrine-Related Cancer</i> , 2012, 19, 497-508.	1.6	13
183	Mice lacking AMP-activated protein kinase $\alpha 1$ catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment. <i>Journal of Endocrinology</i> , 2012, 214, 349-358.	1.2	22
184	Measurement of AMP-Activated Protein Kinase Activity and Expression in Response to Ghrelin. <i>Methods in Enzymology</i> , 2012, 514, 271-287.	0.4	12
185	Familial pituitary adenomas – who should be tested for <i>AIP</i> mutations?. <i>Clinical Endocrinology</i> , 2012, 77, 351-356.	1.2	71
186	Familial isolated pituitary adenomas: An emerging clinical entity. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 1003-1014.	1.8	21
187	Ghrelin Regulation of AMPK in the Hypothalamus and Peripheral Tissues. , 2012, , 91-110.		0
188	Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal $\alpha 7$ Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition. <i>PLoS ONE</i> , 2012, 7, e53339.	1.1	67
189	Genetic studies in a coexistence of acromegaly, pheochromocytoma, gastrointestinal stromal tumor (GIST) and thyroid follicular adenoma. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2012, 56, 507-512.	1.3	17
190	Oncogene-induced senescence in pituitary adenomas and carcinomas. <i>Hormones</i> , 2012, 11, 297-307.	0.9	31
191	Pathogenesis of vascular complications in Cushing's syndrome. <i>Hormones</i> , 2012, 11, 21-30.	0.9	40
192	MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 303, E708-E719.	1.8	71
193	Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. <i>Human Mutation</i> , 2012, 33, 1175-1181.	1.1	74
194	Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1411-E1420.	1.8	122
195	Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor. <i>Pituitary</i> , 2012, 15, 61-67.	1.6	19
196	Paediatric endocrine aspects of ghrelin. <i>Pediatric Endocrinology Reviews</i> , 2012, 9, 628-38.	1.2	3
197	Ghrelin in obesity and endocrine diseases. <i>Molecular and Cellular Endocrinology</i> , 2011, 340, 15-25.	1.6	49
198	Genetic studies on the ghrelin, growth hormone secretagogue receptor (GHSR) and ghrelin O-acyl transferase (GOAT) genes. <i>Peptides</i> , 2011, 32, 2191-2207.	1.2	38

#	ARTICLE	IF	CITATIONS
199	The Immunophilin-Like Protein XAP2 Is a Negative Regulator of Estrogen Signaling through Interaction with Estrogen Receptor α . PLoS ONE, 2011, 6, e25201.	1.1	21
200	The expression of ghrelin O-acyltransferase (GOAT) in human tissues. Endocrine Journal, 2011, 58, 707-710.	0.7	79
201	Specific electrocardiographic features associated with Cushing's disease. Clinical Endocrinology, 2011, 74, 558-564.	1.2	17
202	MicroRNA profile indicates downregulation of the TGF β 2 pathway in sporadic non-functioning pituitary adenomas. Pituitary, 2011, 14, 112-124.	1.6	106
203	The ghrelin/GOAT/GHS-R system and energy metabolism. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 173-186.	2.6	56
204	AIP Mutation in Pituitary Adenomas in the 18th Century and Today. New England Journal of Medicine, 2011, 364, 43-50.	13.9	151
205	AIP and its interacting partners. Journal of Endocrinology, 2011, 210, 137-155.	1.2	124
206	MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas. Endocrine, 2010, 38, 67-75.	1.1	83
207	Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues. Endocrine Pathology, 2010, 21, 25-31.	5.2	12
208	Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. Biochemical Pharmacology, 2010, 80, 1736-1745.	2.0	63
209	Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Human Mutation, 2010, 31, 950-960.	1.1	154
210	Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 698-704.	1.3	23
211	Down-Regulation of Wee1 Kinase by a Specific Subset of microRNA in Human Sporadic Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E181-E191.	1.8	89
212	Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma. Expert Review of Endocrinology and Metabolism, 2010, 5, 681-695.	1.2	11
213	Molecular Genetics of the Aip Gene in Familial Pituitary Tumorigenesis. Progress in Brain Research, 2010, 182, 229-253.	0.9	17
214	Alterations in Adipose Tissue during Critical Illness. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 507-516.	2.5	60
215	Cyclins and their related proteins in pituitary tumourigenesis. Molecular and Cellular Endocrinology, 2010, 326, 25-29.	1.6	18
216	AIP gene and familial isolated pituitary adenomas. Molecular and Cellular Endocrinology, 2010, 326, 71-79.	1.6	46

#	ARTICLE	IF	CITATIONS
217	AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. <i>Bone</i> , 2010, 47, 309-319.	1.4	160
218	Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). <i>Trends in Endocrinology and Metabolism</i> , 2010, 21, 419-427.	3.1	97
219	Ghrelin's Role as a Major Regulator of Appetite and Its Other Functions in Neuroendocrinology. <i>Progress in Brain Research</i> , 2010, 182, 189-205.	0.9	27
220	AMPK as a mediator of hormonal signalling. <i>Journal of Molecular Endocrinology</i> , 2010, 44, 87-97.	1.1	267
221	Regulation of Growth Hormone and Action (Secretagogues). , 2010, , 412-453.		1
222	Down-Regulation of Wee1 Kinase by a Specific Subset of microRNAs in Human Sporadic Pituitary Adenomas. <i>Molecular Endocrinology</i> , 2010, 24, 1886-1886.	3.7	0
223	Recent Clinical and Pathophysiological Advances in Non-Functioning Pituitary Adenomas. <i>Hormone Research in Paediatrics</i> , 2009, 71, 123-130.	0.8	34
224	Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. <i>Endocrine-Related Cancer</i> , 2009, 16, 1329-1338.	1.6	129
225	Shedding light on the intricate puzzle of ghrelin's effects on appetite regulation. <i>Journal of Endocrinology</i> , 2009, 202, 191-198.	1.2	42
226	The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes. <i>European Journal of Endocrinology</i> , 2009, 161, 307-315.	1.9	34
227	Assessment of <i>p27</i> (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (<i>AIP</i>) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable <i>MEN1</i> gene mutations. <i>Clinical Endocrinology</i> , 2009, 70, 259-264.	1.2	60
228	Association Studies on <i>Ghrelin</i> and <i>Ghrelin Receptor</i> Gene Polymorphisms With Obesity. <i>Obesity</i> , 2009, 17, 745-754.	1.5	60
229	A Genetic Study of the Ghrelin and Growth Hormone Secretagogue Receptor (<i>GHSR</i>) Genes and Stature. <i>Annals of Human Genetics</i> , 2009, 73, 1-9.	0.3	18
230	Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. <i>European Journal of Endocrinology</i> , 2009, 161, 655-662.	1.9	42
231	A new variation in the promoter region, the γ 604 C>T, and the Leu72Met polymorphism of the ghrelin gene are associated with protection to insulin resistance. <i>International Journal of Obesity</i> , 2008, 32, 663-668.	1.6	37
232	Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line. <i>Neuroendocrinology</i> , 2008, 87, 168-181.	1.2	114
233	The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2390-2401.	1.8	273
234	AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. <i>FASEB Journal</i> , 2008, 22, 1672-1683.	0.2	148

#	ARTICLE	IF	CITATIONS
235	The role of somatostatin analogues in the treatment of neuroendocrine tumours. <i>Molecular and Cellular Endocrinology</i> , 2008, 286, 238-250.	1.6	47
236	Protein western array analysis in human pituitary tumours: insights and limitations. <i>Endocrine-Related Cancer</i> , 2008, 15, 1099-1114.	1.6	22
237	The potential role of D2 dopamine receptors as a target in the management of neuroendocrine tumors. <i>Cancer Biology and Therapy</i> , 2008, 7, 1979-1981.	1.5	1
238	The Role of AMP-Activated Protein Kinase in Obesity. , 2008, 36, 198-211.		85
239	Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. <i>Endocrine-Related Cancer</i> , 2008, 15, 701-720.	1.6	145
240	HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2673-2678.	0.4	12
241	Changes in Adenosine 5â€²-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushingâ€™s Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4969-4973.	1.8	76
242	Ghrelin Receptor Gene Polymorphisms and Body Size in Children and Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4158-4161.	1.8	21
243	The Yin and Yang of the Ghrelin Gene Products. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2008, 8, 292-302.	0.5	2
244	The Orexigenic Effect of Ghrelin Is Mediated through Central Activation of the Endogenous Cannabinoid System. <i>PLoS ONE</i> , 2008, 3, e1797.	1.1	264
245	Obesity and Metabolism. <i>Frontiers of Hormone Research</i> , 2008, 36, ix.	1.0	4
246	Appetite and Metabolic Effects of Ghrelin and Cannabinoids: Involvement of AMP-Activated Protein Kinase. <i>Vitamins and Hormones</i> , 2007, 77, 121-148.	0.7	27
247	Metabolic and hormonal changes during the refeeding period of prolonged fasting. <i>European Journal of Endocrinology</i> , 2007, 157, 157-166.	1.9	73
248	Ghrelin, the peripheral hunger hormone. <i>Annals of Medicine</i> , 2007, 39, 116-136.	1.5	127
249	Examining the Candidacy of Ghrelin as a Gene Responsible for Variation in Adult Stature in a United Kingdom Population with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2201-2204.	1.8	7
250	A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. <i>Clinical Endocrinology</i> , 2007, 66, 348-352.	1.2	63
251	Ghrelin in neuroendocrine organs and tumours. <i>Pituitary</i> , 2007, 10, 213-225.	1.6	37
252	Ghrelin and cardiovascular health. <i>Current Opinion in Pharmacology</i> , 2006, 6, 142-147.	1.7	57

#	ARTICLE	IF	CITATIONS
253	Expanding role of AMPK in endocrinology. Trends in Endocrinology and Metabolism, 2006, 17, 205-215.	3.1	190
254	PPAR- γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR- γ receptor. Clinical Endocrinology, 2006, 65, 389-395.	1.2	37
255	Macro- and micronutrient losses and nutritional status resulting from 44 days of total fasting in a non-obese man. Nutrition, 2006, 22, 889-897.	1.1	27
256	Effect of Gastric Bypass and Gastric Banding on Proneurotensin Levels in Morbidly Obese Patients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3544-3547.	1.8	46
257	The Farnesoid X Receptor Is Expressed in Breast Cancer and Regulates Apoptosis and Aromatase Expression. Cancer Research, 2006, 66, 10120-10126.	0.4	157
258	Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. European Journal of Endocrinology, 2006, 155, 371-379.	1.9	100
259	A HIF1 α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genetics, 2005, 1, e8.	1.5	394
260	Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocrine-Related Cancer, 2005, 12, 423-433.	1.6	117
261	Differential gene expression in pituitary adenomas by oligonucleotide array analysis. European Journal of Endocrinology, 2005, 153, 143-151.	1.9	113
262	Refeeding David Blaine "Studies after a 44-Day Fast. New England Journal of Medicine, 2005, 353, 2306-2307.	13.9	23
263	Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase. Journal of Biological Chemistry, 2005, 280, 25196-25201.	1.6	425
264	Theobromine inhibits sensory nerve activation and cough. FASEB Journal, 2005, 19, 1-16.	0.2	98
265	Fasting and Postprandial Hyperghrelinemia in Prader-Willi Syndrome Is Partially Explained by Hypoinsulinemia, and Is Not Due to Peptide YY3 α 6 Deficiency or Seen in Hypothalamic Obesity Due to Craniopharyngioma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2681-2690.	1.8	108
266	Non-Growth Hormone Endocrine Actions of Ghrelin. , 2004, , 73-89.		0
267	Elevated Fasting Plasma Ghrelin in Prader-Willi Syndrome Adults Is Not Solely Explained by Their Reduced Visceral Adiposity and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1718-1726.	1.8	107
268	Ghrelin: update on a novel hormonal system. European Journal of Endocrinology, 2004, 151 Suppl 1, S67-S70.	1.9	63
269	Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. European Journal of Endocrinology, 2004, 151, 233-240.	1.9	121
270	Acting and Cycling: A Tale of the Pituitary. Hormone Research in Paediatrics, 2004, 62, 117-123.	0.8	7

#	ARTICLE	IF	CITATIONS
271	A Comparison of a Novel Testosterone Bioadhesive Buccal System, Striant, with a Testosterone Adhesive Patch in Hypogonadal Males. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2039-2043.	1.8	64
272	Striant [®] , a SR: a novel, effective and convenient testosterone therapy for male hypogonadism. <i>International Journal of Clinical Practice</i> , 2004, 58, 1073-1080.	0.8	18
273	The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. <i>British Journal of Pharmacology</i> , 2004, 143, 520-523.	2.7	162
274	Ghrelin? a hormone with multiple functions. <i>Frontiers in Neuroendocrinology</i> , 2004, 25, 27-68.	2.5	496
275	Cell Cycle Dysregulation in Pituitary Oncogenesis. , 2004, 32, 34-62.		58
276	Role of Regulatory Factors in Pituitary Tumour Formation. , 2004, 32, 63-95.		19
277	Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. <i>Clinical Endocrinology</i> , 2003, 58, 572-580.	1.2	19
278	Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. <i>Clinical Endocrinology</i> , 2003, 59, 328-338.	1.2	37
279	Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 743-747.	1.8	21
280	Identification of Adrenocorticotropin Receptor Messenger Ribonucleic Acid in the Human Pituitary and Its Loss of Expression in Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 6080-6087.	1.8	43
281	Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. <i>Journal of Endocrinology</i> , 2003, 176, 103-110.	1.2	35
282	Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours. <i>Journal of Endocrinology</i> , 2003, 178, 301-310.	1.2	21
283	The Kr ² ppel-like transcription factor 6 gene in sporadic pituitary tumours.. <i>Endocrine-Related Cancer</i> , 2003, 10, 397-402.	1.6	12
284	Ghrelin is Released from Rat Hypothalamic Explants and Stimulates Corticotrophin-releasing Hormone and Arginine-vasopressin. <i>Hormone and Metabolic Research</i> , 2003, 35, 455-459.	0.7	117
285	The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2988-2991.	1.8	1,082
286	A Variation in the Ghrelin Gene Increases Weight and Decreases Insulin Secretion in Tall, Obese Children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4005-4008.	1.8	141
287	Expression of Phosphorylated p27 ^{Kip1} Protein and Jun Activation Domain-Binding Protein 1 in Human Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2635-2643.	1.8	102
288	Cell Cycle Dysregulation in Human Pituitary Tumours. <i>Clinical Science</i> , 2002, 103, 22P-22P.	0.0	0

#	ARTICLE	IF	CITATIONS
289	Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. <i>Clinical Endocrinology</i> , 2002, 57, 443-448.	1.2	72
290	The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors. <i>Pituitary</i> , 2002, 5, 235-242.	1.6	16
291	Optimal Response Criteria for the Human CRH Test in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1640-1645.	1.8	76
292	Response of Serum Macrophage Migration Inhibitory Factor Levels to Stimulation or Suppression of the Hypothalamo-Pituitary-Adrenal Axis in Normal Subjects and Patients with Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1834-1840.	1.8	23
293	The release of leptin and its effect on hormone release from human pituitary adenomas. <i>Clinical Endocrinology</i> , 2001, 54, 781-789.	1.2	36
294	Leptin and puberty: a review. <i>Pituitary</i> , 2001, 4, 79-86.	1.6	40
295	Presence of Ghrelin in Normal and Adenomatous Human Pituitary. <i>Endocrine</i> , 2001, 14, 101-104.	2.2	115
296	Imprinting of the Gs α gene GNAS1 in the pathogenesis of acromegaly. <i>Journal of Clinical Investigation</i> , 2001, 107, R31-R36.	3.9	266
297	The Expression of the Growth Hormone Secretagogue Receptor Ligand Ghrelin in Normal and Abnormal Human Pituitary and Other Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 881-887.	1.8	210
298	Expression of 11 β -Hydroxysteroid Dehydrogenase Isoenzymes in the Human Pituitary: Induction of the Type 2 Enzyme in Corticotropinomas and Other Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2728-2733.	1.8	52
299	How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?. <i>Clinical Endocrinology</i> , 2000, 53, 493-500.	1.2	91
300	Expression of the Pituitary Transcription Factor Ptx-1, But Not That of the Trans-Activating Factor Prop-1, Is Reduced in Human Corticotroph Adenomas and Is Associated with Decreased α -Subunit Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2537-2542.	1.8	10
301	The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2489-2495.	1.8	96
302	Expression of menin gene mRNA in pituitary tumours. <i>European Journal of Endocrinology</i> , 1999, 140, 358-361.	1.9	29
303	Hexarelin as a test of pituitary reserve in patients with pituitary disease. <i>Clinical Endocrinology</i> , 1999, 51, 369-375.	1.2	21
304	The Effect of Growth Hormone Secretagogues and Neuropeptide Y on Hypothalamic Hormone Release from Acute Rat Hypothalamic Explants. <i>Journal of Neuroendocrinology</i> , 1999, 11, 521-528.	1.2	73
305	The Effects of GH-Secretagogues on Human Pituitary Cells in Culture and on Rat Hypothalamic Tissue. , 1999, , 65-77.		2
306	Leptin and the thyroid - A puzzle with missing pieces. <i>Clinical Endocrinology</i> , 1998, 49, 569-572.	1.2	28

#	ARTICLE	IF	CITATIONS
307	Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3624-3630.	1.8	75
308	Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3624-3630.	1.8	64
309	Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary-adrenal activity. Clinical Endocrinology, 1997, 46, 751-757.	1.2	128
310	Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. Clinical Endocrinology, 1996, 45, 699-706.	1.2	53
311	L-Arginine is unlikely to exert neuroendocrine effects in humans via the generation of nitric oxide. European Journal of Endocrinology, 1996, 135, 543-547.	1.9	26
312	The effect of an opiate antagonist on the hormonal changes induced by hexarelin. Clinical Endocrinology, 1995, 43, 365-371.	1.2	52
313	Growth hormone-releasing peptide and its analogues. Trends in Endocrinology and Metabolism, 1995, 6, 43-49.	3.1	115
314	Determination of Direct Effects of Cytokines on Release of Neuropeptides from Rat Hypothalamus by an in Vitro Method. Methods in Neurosciences, 1993, 16, 302-326.	0.5	1
315	Glioma in an AIP mutation carrier patient. Endocrine Abstracts, 0, , .	0.0	1
316	Polymorphism or mutation? - The role of the R304Q missense AIP mutation in the predisposition to pituitary adenoma. Endocrine Abstracts, 0, , .	0.0	2
317	Changes in pituitary tumour biology and behaviour in FIPA patient with GH secreting aggressive pituitary macro adenoma. Endocrine Abstracts, 0, , .	0.0	2
318	Investigating the role of AIP in mouse pituitary adenoma formation. Endocrine Abstracts, 0, , .	0.0	3
319	Identifying disease causing variants in aryl hydrocarbon receptor-interacting protein (AIP) variants and their significance on the clinical phenotypes. Endocrine Abstracts, 0, , .	0.0	1
320	Investigating the role of AIP in pituitary tumourigenesis. Endocrine Abstracts, 0, , .	0.0	1
321	Unusual cause of gigantism - Growth hormone releasing hormone (GHRH)-secreting pancreatic neuroendocrine tumour in a patient with multiple endocrine neoplasia type 1 (MEN1). Endocrine Abstracts, 0, , .	0.0	1
322	Phenotypic differences between patients with familial pituitary neuroendocrine tumours due to MEN1 or AIP mutations. Endocrine Abstracts, 0, , .	0.0	1